China's securities regulator approved Unitree Robotics' IPO registration on 2 July, clearing the Hangzhou-based humanoid maker to list on Shanghai's STAR Market [E1]. The company plans to raise about RMB 4.2 billion, roughly $619 million, from the offering [E2]. Proceeds are earmarked for robot AI-model research, robot-body development, new products, and a smart-robot manufacturing base [E2]. The allocation treats capital as fuel for hardware scale and domestic production capacity [E2].
Figure deployed its Figure 03 robot at BMW Group Plant Spartanburg and advanced to a harder sequencing workflow [E3]. The task requires arranging parts that arrive in variable orientations, a step beyond repetitive motions that dominated earlier trials [E3]. Figure said its earlier model contributed to assembling 30,000 cars at BMW last year [E3]. The Spartanburg assignment links embodied AI to measurable throughput on an active assembly line [E3].
UBTech launched an AI-powered companion robot line the same week, pricing torso-only U1 units from RMB 119,800 and full-size models up to RMB 990,000 [E4]. The spread positions humanoid hardware as a luxury consumer purchase alongside industrial trials [E4]. The launch adds a retail wedge next to Unitree's factory-focused raise and Figure's BMW sequencing work [E4].
Within days of one another, Unitree secured listing approval, Figure upgraded its BMW assignment, and UBTech opened a consumer price list spanning two orders of magnitude [E1][E3][E4]. The announcements compress capital access, factory integration, and retail positioning into one news cycle [E2][E3][E4]. Taken together, they sketch a humanoid contest increasingly shaped by production economics [E1][E2][E3].
Near-term advantage may flow to makers who pair affordable robot bodies and reachable domestic supply chains with listed-market capital and live factory workflows [E1][E2][E3]. Unitree's manufacturing-base spend and Figure's variable-orientation task both invest in embodied throughput [E2][E3]. This week's capital raises and plant assignments reward makers who can fund robot bodies at scale and deliver repeatable factory work [E1][E2][E3].
Chinese humanoid builders are pursuing parallel tracks in factory automation, public financing, and high-priced companions [E1][E2][E4]. Unitree's IPO path opens a domestic funding channel that many Western peers still reach through private rounds [E1][E2]. UBTech's six-figure price tags test demand outside automotive and logistics clients [E4]. The split maps distinct bets on where embodied AI earns payback first [E2][E4].
Skeptics nonetheless warn that regulatory clearance and a plant pilot remain distant from profitable deployment at scale [E1][E3]. General-purpose dexterity is still unsolved, and a harder BMW sequencing task does not by itself prove margin-positive factory economics [E3]. UBTech's companion push can signal confidence in a new revenue lane or a hedge against thin industrial orders [E4]. IPO proceeds and assembly-line headlines document ambition and access, not a settled winner in embodied AI [E1][E2][E3][E4].
Domestic component sourcing sits at the center of Unitree's manufacturing-base plan [E2]. STAR Market proceeds explicitly fund robot-body research alongside AI models, implying hardware cost curves bind scale as tightly as model quality [E2]. Programs at BMW and listings in Shanghai both treat the robot chassis as the scarce input in embodied AI [E2][E3].